Connect Biopharma Holdings Limited CNTB
0.63 USD -0.04 (-5.56%)
Regular-session close
0.61 -0.02 -3.06%
After hours · Nov 19, 6:41 PM ET
0.591 Day range 0.65
0.55 52-week range 3.82
- YTD
- -77.72%
- 1 year
- -80.06%
News
benzinga.com Piper Sandler Maintains Overweight on Connect Biopharma Hldgs, Lowers Price Target to $5 Piper Sandler analyst Biren Amin maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Overweight and lowers the price target from $7 to $5.
benzinga.com Connect Biopharma Hldgs Q3 EPS $(0.26) Beats $(0.27) Estimate, Sales $736.000K Miss $771.429K Estimate Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.27) by 3.7 percent. This is a 16.13 percent increase over losses…
globenewswire.com Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update – Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and chronic obstructive…benzinga.com HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
seekingalpha.com Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript
zacks.com Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround Connect Biopharma Holdings (CNTB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising…
zacks.com Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher Connect Biopharma Holdings (CNTB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate…
defenseworld.net Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and Connect Biopharma (NASDAQ: CNTB - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast…
marketbeat.com Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures Connect Biopharma NASDAQ: CNTB reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease,…
benzinga.com Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy Connect Biopharma Holdings Limited (NASDAQ:CNTB) recently shared positive topline results from its global Phase 2 study.
seekingalpha.com Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
globenewswire.com Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation – Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) –
seekingalpha.com Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
benzinga.com Why Is Connect Biopharma Stock Trading Lower on Tuesday? Connect Biopharma Holdings Limited (NASDAQ:CNTB) stock hit its 52-week low on Tuesday after releasing topline results from its global Phase 2 study evaluating rademikibart.
globenewswire.com Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation – Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day…
globenewswire.com Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on…
globenewswire.com Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update – Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – –…
defenseworld.net Brokerages Set Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Price Target at $7.29 Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight brokerages that are covering the firm,…
seekingalpha.com Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster Dupixent. The company is approaching a readout from two trials, Seabreeze STAT Asthma and…
globenewswire.com Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma – On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet…
marketbeat.com Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026 Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits…
globenewswire.com Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on…
globenewswire.com Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update – Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –
